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Abstract 
Gold(III) complexes with 1,7- and 4,7-phenanthroline ligands, [AuCl3(1,7-phen-κN7)] (1) 
and [AuCl3(4,7-phen-κN4)] (2) were synthesized and structurally characterized by 
spectroscopic (NMR, IR and UV-vis) and single-crystal X-ray diffraction techniques. In 
these complexes, 1,7- and 4,7-phenanthrolines are monodentatedly coordinated to the 
Au(III) ion through the N7 and N4 nitrogen atoms, respectively. In comparison to the 
clinically relevant anti-angiogenic compounds auranofin and sunitinib, gold(III)-
phenanthroline complexes showed from 1.5- to 20-fold higher anti-angiogenic potential, 
and 13- and 118-fold lower toxicity. Among the tested compounds, complex 1 was the 
most potent and may be an excellent anti-angiogenic drug candidate, since it showed 
strong anti-angiogenic activity in zebrafish embryos achieving IC50 value (concentration 
resulting in an anti-angiogenic phenotype at 50% of embryos) of 2.89 µM, while had low 
toxicity with LC50 value (the concentration inducing the lethal effect of 50% embryos) of 
128 µM. Molecular docking study revealed that both complexes and ligands could 
suppress angiogenesis targeting the multiple major regulators of angiogenesis, such as the 
vascular endothelial growth factor receptor (VEGFR-2), the matrix metalloproteases 
(MMP-2 and MMP-9), and thioredoxin reductase (TrxR1), where the complexes showed 
higher binding affinity in comparison to ligands, and particularly to auranofin, but 
comparable to sunitinib, an anti-angiogenic drug of clinical relevance. 
 
Keywords: Gold(III) complexes, Phenanthroline, Cytotoxicity, Embryotoxicity, Angiogenesis 
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                [AuCl3(1,7-phen-κN7)] (1)                                          [AuCl3(4,7-phen-κN4)] (2) 
 
Fig. S1. The structures of mononuclear gold(III) complexes 1 and 2 calculated at the M06-
2X(CPCM)/cc-pVTZ+LanL2TZ(f) level of theory.  
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Fig. S2. Optimized geometries of the chemical species involved in the reaction of [AuCl4]
- 
with 1,7-phen in 2 : 1 molar ratio, respectively, calculated at the M06-2X(CPCM)/cc-
pVTZ+LanL2TZ(f) level of theory. The reaction pathway is the following: RC1,7-phen 
(reactant complex) → TS1,7-phen-1 (transition state 1) → IC1,7-phen (intermediate complex) → 
TS1,7-phen-2 (transition state 2) → PC1,7-phen (product complex). 
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Fig. S3. Optimized geometries of the chemical species involved in the reaction of [AuCl4]
- 
with 4,7-phen in 2 : 1 molar ratio, respectively, calculated at the M06-2X(CPCM)/cc-
pVTZ+LanL2TZ(f) level of theory. The reaction pathway is the following: RC4,7-phen 
(reactant complex) → TS4,7-phen-1 (transition state 1) → IC4,7-phen (intermediate complex) → 
TS4,7-phen-2 (transition state 2) → PC4,7-phen (product complex).  
 
 
 
Supplementary Information 
S9 
 
 
 
 
 
 
 
 
 
 
 
Fig. S4. Energy diagram of the reactions of [AuCl4]
- with 1,7-phen (A) and 4,7-phen (B) in 
2 : 1 molar ratio, respectively. Relative free energies (M06-2X(CPCM)/cc-
pVTZ+LanL2TZ(f)) were computed with respect to the corresponding reactant complex. 
For more details see Figs. S2 and S3. 
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Fig. S5. The anti-angiogenic phenotype of zebrafish embryos defined as effect of different 
concentrations of gold(III)-phenanthroline complexes 1 and 2, the respective 1,7-and 4,7-
phen ligands and K[AuCl4] on the ISVs development. 1.25 µM auranofin and sunitinib 
were used as positive controls. 
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Fig. S6. The inhibition of ISVs and SIVs angiogenesis upon treatments with different 
concentrations of gold(III)-phenanthroline complexes 1 and 2, the respective 1,7- and 4,7-
phen ligands and K[AuCl4] on the ISVs development. 1.25 µM auranofin and sunitinib 
were used as positive controls.  
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Fig. S7. The effect of different concentrations of gold(III)-phenanthroline complexes 1 and 
2, the respective 1,7- and 4,7-phen ligands and K[AuCl4] on the heart beating rate of 
zebrafish embryos (n = 30). Auranofin and sunitinib applied in the concentration of 1.25 
µM were used as positive controls. 
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Fig. S8. Therapeutic window (TW) of gold(III)-phenanthroline complexes 1 and 2, the 
respective 1,7- and 4,7-phen ligands, K[AuCl4], auranofin and sunitinib assessed as the 
ratio of LC50 and IC50. Respective TW values are presented above each of tested 
compounds.  
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Fig. S9. The binding of gold(III) complexes 1 and 2, 1,7- and 4,7-phen, auranofin and 
sunitinib in the active site of VEGFR-2 protein as assessed by molecular docking. 
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Fig. S10. The binding of gold(III) complexes 1 and 2, 1,7- and 4,7-phen, auranofin and 
sunitinib in the active site of MMP-2 protein as assessed by molecular docking. 
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Fig. S11. The binding of gold(III) complexes 1 and 2, 1,7- and 4,7-phen, auranofin and 
sunitinib in the active site of MMP-9 protein as assessed by molecular docking. 
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Fig. S12. The binding of gold(III) complexes 1 and 2, 1,7- and 4,7-phen, auranofin and 
sunitinib in the active site of the protein thioredoxin reductase 1 (TrxR1) as assessed by 
molecular docking.  
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Fig. S13. Interactions of gold(III) complexes 1 and 2, 1,7- and 4,7-phen, auranofin and 
sunitinib with VEGFR-2 protein during molecular docking.   
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Fig. S14. Interactions of gold(III) complexes 1 and 2, 1,7- and 4,7-phen, auranofin and 
sunitinib with MMP-2 protein during molecular docking.  
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Fig. S15. Interactions of gold(III) complexes 1 and 2, 1,7- and 4,7-phen, auranofin and 
sunitinib with MMP-9 protein during molecular docking.   
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Fig. S16. Interactions of gold(III) complexes 1 and 2, 1,7- and 4,7-phen, auranofin and 
sunitinib with selenocysteine residue of TrxR1 protein during molecular docking.  
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Table S1 
Crystal data for 1 and 2. 
For all structures: C12H8AuCl3N2, Mr = 483.52. Experiments were carried out at 295 K 
with Mo Kα radiation. H-atom parameters were constrained. 
 1 2 
Crystal data 
Crystal system, space group Monoclinic, P21/c Triclinic, P  
a, b, c (Å) 12.1848(3), 14.1996(3), 7.7110(2) 7.8420(12), 8.8631(14), 10.7500(5) 
, ,  (°) 90, 95.833(2), 90 78.707(8), 87.300(8), 66.988(15) 
V (Å3) 1327.24(6) 674.04(17) 
Z 4 2 
Dx (Mg m-3) 2.420 2.382 
 (mm-1) 11.67 11.49 
Crystal size (mm) 0.18 × 0.05 × 0.03 0.18 × 0.05 × 0.03 
Data collection 
Absorption correction Analytical  Multi-scan  
 Tmin, Tmax 0.093, 0.780 0.903, 1.000 
No. of measured, independent and 
 observed [I > 2(I)] reflections 
18485, 2336, 2126   4091, 4091, 3247   
Rint 0.041  
(sin /)max (Å-1) 0.595 0.596 
Refinement 
R[F2 > 2(F2)], wR(F2), S 0.019,  0.044,  1.08 0.036,  0.083,  0.93 
No. of reflections 2336 4091 
No. of parameters 163 164 
max, min (e Å-3) 0.83, -0.56 1.08, -0.87 
Percent Filled Space (K.P.I.) (%)a 69.2 67.9 
aFor definition see: A.I. Kitajgorodskij, Molecular Crystals and Molecules, New-York, Academic 
Press, 1973. 
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Table S2  
Lethal and teratogenic effects observed in zebrafish (Danio rerio) embryos at different 
hours post fertilization (hpf). 
Category   Developmental endpoints  Exposure time (hpf) 
    24  48  72  96/114 
        Lethal effect  Egg coagulationa  ● ● ● ● 
  No somite formation  ● ● ● ● 
  Tail not detached  ● ● ● ● 
  No heartbeat   ● ● ● 
        
Teratogenic effect  Malformation of head  ● ● ● ● 
  Malformation of eyesb  ● ● ● ● 
  Malformation of sacculi/otolithsc  ● ● ● ● 
  Malformation of chorda  ● ● ● ● 
  Malformation of taild  ● ● ● ● 
  Scoliosis  ● ● ● ● 
  Heartbeat frequency   ● ● ● 
  Blood circulation   ● ● ● 
  Pericardial edema  ● ● ● ● 
  Yolk edema  ● ● ● ● 
  Yolk absosrption  ● ● ● ● 
  Growth retardatione  ● ● ● ● 
aNo clear organs structure is recognized. 
bMalformation of eyes was recorded for the retardation in eye development and abnormality in 
shape and size. 
cPresence of no, one or more than two otoliths per sacculus, as well as reduction and enlargement 
of otoliths and/or sacculi (otic vesicles). 
dTail malformation was recorded when the tail was bent, twisted or shorter than to control embryos 
as assessed by optical comparation. 
eGrowth retardation was recorded by comparing with the control embryos in development or size 
(before hatching, at 24 and 48 hpf) or in a body length (after hatching, at and onwards 72 hpf) using 
by optical comparation using an inverted microscope (CKX41; Olympus, Tokyo, Japan). 
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Table S3  
Selected bond distances (Å) and valence angles (o) of the gold(III) complexes 1 and 2. 
 1 2 
X-ray DFT-calculated X-ray DFT-calculated 
Au—Na 2.049(3) 2.0477 2.066(7) 2.0490 
Au—Cl1 2.2858(10) 2.3007 2.284(3) 2.3005 
Au—Cl2 2.2643(10) 2.2789 2.273(2) 2.2788 
Au—Cl3 2.2701(12) 2.2993 2.273(3) 2.2997 
     
N—Au—Cl1 89.64(9) 89.0716 89.5(2) 89.1026 
N—Au—Cl2 178.07(10) 178.6975 179.9(3) 178.4938 
N—Au—Cl3 88.90(9) 88.7922 88.9(2) 88.7689 
Cl1—Au—Cl2 90.29(4) 91.1128 90.58(11) 91.0814 
Cl1—Au—Cl3 178.49(4) 177.8293 176.79(11) 177.8456 
Cl2—Au—Cl3 91.16(4) 91.0316 91.04(11) 91.0551 
Au—N—C6a 121.0(2) 121.8445   
Au—N—C8 118.4(3) 116.9398   
Au—N—C4a   122.2(6) 122.0368 
Au—N—C3   116.1(6) 116.5949 
aN7 for the complex 1 and N4 for the complex 2. 
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Table S4  
Geometrical parameters describing intermolecular interactions in the crystals of 1 and 2a,b.  
 
D–H 
[Å] 
D···A [Å] H···A [Å] 
D-H···A 
[°] 
Symmetry 
operations on A 
1      
C2–H2···N1 0.93                 3.632(5) 2.79 151 -x+1,-y+2,-z+1 
C3–H3···Cl1 0.93             3.753(5) 2.87 158 -x+1,+y+1/2,-z+1/2+1 
C4–H4···Cl3 0.93               3.832(4) 2.92 166 -x+1,-y+1,-z+1 
C8–H8···Cl1 0.93            3.705(4) 2.87 150 -x,-y+1,-z+1 
C9–H9···Cl1 0.93                3.600(4) 2.96 127 x,-y+1/2+1,+z-1/2 
C9–H9···Cl2 0.93                3.701(4) 2.93 141 -x,+y+1/2,-z+1/2 
2      
C2–H2···N7 0.93             3.398(13) 2.48 171 x+1,+y-1,+z 
C9–H9···Cl1 0.93             3.713(12) 2.87 151 -x,-y+1,-z 
C9–H9···Cl3 0.93             3.544(11) 2.88 129 -x+1,-y+1,-z 
C8–H8···Cl2 0.93             3.820(10) 2.92 164 x-1,+y+1,+z-1 
C5–H5···Cl3 0.93             3.573(12) 2.84 137 -x+1,-y+1,-z+1 
C3–H3···Cl1 0.93             3.713(9) 2.83 160 -x+1,-y,-z+1 
C1–H1···Cl2 0.93             3.778(11) 2.88 163 x,+y,+z-1 
 
Cl···Cl 
Au···Cl 
X···X [Å] d [Å] θ1 / θ2 [°] type 
Symmetry 
operations 
1 Cl1···Cl3 3.4374(16) 149.30(6) /  
149.01(7) 
I x,+y,+z+1 
 Cl1···Au1 3.4074(11)   -x,-y+1,-z+1 
2 Cl1···Cl3 3.534(4) 150.35(14) / 
152.35(15) 
I x-1,+y,+z 
 Cl1···Au1 3.786(3)   -x+1,-y,-z+1 
 
Off-Face 
stacking 
 
h [Å] r [Å] θ [°] 
Symmetry 
operations 
1  3.887 0.404 14 x,-y+1/2+1,+z-1/2 
2  3.486 1.613 0 -x,-y+1,-z 
aFor description of parameters describing the halogen bonds see G.R. Desiraju, R. Parthasarathy, J. 
Am. Chem. Soc. 111 (1989) 8725-8726; A. Mukherjee, S. Tothadi, G.R. Desiraju, Acc. Chem. Res. 
47 (2014) 2514-2524. 
bFor description of parameters describing stacking interactions see M. L. Główka, D. Martynowski, 
K. Kozłowska, J. Mol. Struct. 474 (1999) 81-89. 
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Table S5 
Crucial interatomic distances (Å) in the structures involved in the mechanism of the reaction of [AuCl4]
- with 1,7- and 4,7-phen calculated at the 
M06-2X/cc-PVTZ+LanL2TZ(f) level of theory. 
 Au1—N7 Au1—Cl1 Au1—Cl2 Au1—Cl3 Au1—Cl7 
 
Au2—N1 
 
Au2—Cl4 
 
Au2—Cl5 
 
Au2—Cl6 
 
Au2—Cl8 
 
RC1,7-phen 2.9590 2.3100 2.3106 2.3088 2.3085 3.2725 2.3063 2.3080 2.3061 2.3055 
TS1,7-phen -1 2.3957 2.3005 2.3278 2.2963 2.6415 3.1989 2.3048 2.3081 2.3067 2.3042 
IC1,7-phen 2.0507 2.3053 2.2929 2.3081 3.2298 3.4059 2.3037 2.3048 2.3085 2.3028 
TS1,7-phen -2 2.0549 2.3051 2.2878 2.3082 3.2150 2.4048 2.2980 2.3069 2.2961 2.7140 
PC1,7-phen 2.0637 2.3078 2.2862 2.3057 3.1860 2.0838 2.3062 2.2788 2.3079 3.2069 
 Au1—N4 Au1—Cl1 Au1—Cl2 Au1—Cl3 Au1—Cl7 
 
Au2—N7 
 
Au2—Cl4 
 
Au2—Cl5 
 
Au2—Cl6 
 
Au2—Cl8 
 
RC4,7-phen 2.9611 2.3111 2.3091 2.3113 2.3088 2.9622 2.3113 2.3091 2.3112 2.3089 
TS4,7-phen -1 2.4037 2.2994 2.3253 2.2955 2.6426 2.9530 2.3097 2.3089 2.3088 2.3084 
IC4,7-phen 2.0538 2.3068 2.2884 2.3062 3.2286 2.9503 2.3092 2.3098 2.3084 2.3083 
TS4,7-phen -2 2.0574 2.3057 2.2871 2.3076 3.1974 2.3957 2.2952 2.3173 2.3000 2.6631 
PC4,7-phen 
 
2.0628 2.3044 2.2846 2.3079 3.1876 2.0627 2.3046 2.2846 2.3076 3.1877 
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Table S6 
Evaluation of anti-angiogenic potential of gold(III) complexes in comparison to 1,7- and 
4,7-phenanthroline, K[AuCl4] and clinically used drugs auranofin and sunitinib. 
 Affected 
embryos (%)a 
 ISVs (number)  Inhibition (%) 
Compound  Intact Defective Absent  ISVs SIVs 
DMF (0.035%) 3.3 ± 0.6  28.4 ± 0.7 0.5 ± 0.7 0.0 ± 0.0  0.3 ± 1.1 0.1 ± 0.03 
[AuCl3(1,7-phen-κN7)] (1)        
20 µM 100.0 ± 0.0  0.3 ± 0.5 13.5 ± 1.2 14.2 ± 0.9  77.3 ± 1.1 100 ± 0.0 
10 µM 100.0 ± 0.0  5.2 ± 1.1 19.0 ± 1.6 3.8 ± 0.8  51.9 ± 2.7 80.2 ± 0.3 
5 µM 63.3 ± 5.1  17.3 ± 0.8 9.0 ± 0.7 1.9 ± 0.6  45.8 ± 3.6 74.2 ± 1.0 
2.5 µM 50.0 ± 3.3  20.7 ± 1.3 5.3 ± 1.1 2.1 ± 0.9  39.4 ± 1.9 58.5 ± 1.8 
1,7-phen         
20 µM 96.7 ± 4.3  17.7 ± 1.6 8.4 ± 0.8 1.9 ± 1.6  47.8 ± 1.1 55.3 ± 1.9 
10 µM 56.7 ± 1.9  20.1 ± 0.9 6.1 ± 01 2.0 ± 0.7  32.8 ± 1.8 44.5 ± 3.0 
5 µM 10.0 ± 2.1  25.1 ± 0.7 1.9 ± 0.7 1.0 ± 0.7  25.4 ± 2.0 29.6 ± 3.8 
2.5 µM 3.3 ± 0.6  28.0 ± 0.1 0.0 ± 0.0 0.1 ± 0.3  13.1 ± 1.2 13.0 ± 0.6 
[AuCl3(4,7-phen-κN4)] (2)        
20 µM 100.0 ± 0.0  9.0 ± 1.1 10.7 ± 1.3 8.3 ± 1.6  64.3 ± 0.8 86.3 ± 0.1 
10 µM 90.0 ± 0.0  14.4 ± 1.3 11.5 ± 1.2 2.3 ± 0.8  52.1 ± 0.3 76.8 ± 0.4 
5 µM 46.7 ± 2.1  21.2 ± 2.5 7.2 ± 0.8 0.3 ± 0.5  41.3 ± 4.1 49.3 ± 0.1 
2.5 µM 20.0 ± 2.7  24.0 ± 0.9 4.1 ± 1.1 0.1 ± 0.3  33.4 ± 1.6 37.4 ± 0.8 
4,7-phen         
20 µM 76.7 ± 4.2  15.2 ± 0.6 10.9 ± 0.7 1.9 ± 1.1  32.6 ± 0.8 51.3 ± 0.5 
10 µM 43.3 ± 1.7  16.8 ± 1.2 9.1 ± 1.1 2.2 ± 0.8  20.7 ± 2.1 36.6 ± 0.7 
5 µM 6.7 ± 1.2  27.5 ± 0.9 0.5 ± 0.2 0.0 ± 0.0  18.2 ± 3.0 33.0 ± 0.1 
2.5 µM 0.0 ± 0.0  28.3 ± 0.5 0.0 ± 0.0 0.0 ± 0.0  8.8 ± 0.4 5.8 ± 1.0 
K[AuCl4]         
20 µM 30. ± 5.8  25.6 ± 1.1 2.4 ± 1.1 0.0 ± 0.0  6.7 ± 0.6 2.7 ± 0.5 
Auranofin         
1.25 µM 100.0 ± 0.0  13.0 ± 1.1 13.6 ± 0.7 1.6 ± 1.1  31.8 ± 1.7 58.0 ± 0.3 
Sunitinib         
1.25 µM 100.0 ± 0.0  7.9 ± 1.2 17.7  ± 
1.1 
2.4 ± 0.5  32.9 ± 4.1 59.0 ± 0.4 
aThe percentage of zebrafish embryos displaying anti-angiogenic phenotype.  
 
 
